Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
CAP-1002 Allogeneic Cardiosphere-Derived Cells
BIOLOGICAL
2 trials
Sponsors
Capricor Inc.
Conditions
COVID-19
Myocardial Infarction
Phase 1
Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
Terminated
NCT01458405
Capricor Inc.
Myocardial Infarction
Start: 2012-11-13
End: 2019-02-28
Updated: 2024-04-09
Unknown Phase
CAP-1002 in Severe COVID-19 Disease
NCT04338347
Capricor Inc.
COVID-19
Updated: 2020-12-01
Related Papers
Effect of cardiosphere-derived cells on segmental myocardial function after myocardial infarction: ALLSTAR randomised clinical trial
Open Heart
2021-07-01
31 citations
Abstract 12730: Cardiosphere-derived Cells Improve Segmental Myocardial Circumferential Strain by Magnetic Resonance Imaging: Results From the Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration Study
Circulation
2020-11-12
Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial
European Heart Journal
2020-06-25
118 citations
Dose-dependent improvement of cardiac function in a swine model of acute myocardial infarction after intracoronary administration of allogeneic heart-derived cells.
2019-05-31
31 citations